肿瘤细胞治疗研究
英文原题：Advances in immunotherapy in cervical cancer.
宫颈癌是一个重大的公共卫生问题，是全球女性发病率和死亡率第四常见的癌症。
宫颈癌是一个重大的公共卫生问题，是全球女性发病率和死亡率第四高的常见癌症。复发、持续或转移性且不适合根治性治疗方法的患者预后极差。直到最近，这些患者仅适合接受以顺铂为基础的化疗联合贝伐珠单抗。然而，免疫检查点抑制剂的引入彻底改变了该疾病的治疗，在铂类治疗后和一线治疗中均实现了历史性的总生存改善。有趣的是，宫颈癌免疫治疗的临床开发目前正在向局部晚期推进，尽管迄今为止该领域的初步疗效结果令人失望。此外，早期试验中关于新型免疫治疗方法，如人乳头瘤病毒治疗性疫苗和过继细胞疗法，正在涌现出有前景的数据。本综述总结了近年来在免疫治疗领域开展的主要临床试验。
Cervical cancer represents a major public health problem, being the fourth most common cancer in incidence and mortality in women worldwide. Patients with recurrent, persistent, or metastatic disease unsuitable for curative therapeutic approaches have a dismal prognosis. Until recently, these patients were only candidates for cisplatin-based chemotherapy plus bevacizumab. However, the introduction of immune checkpoint inhibitors has revolutionized the treatment of this disease, achieving historical overall survival improvements in both the post-platinum and front-line settings. Interestingly, the clinical development of immunotherapy in cervical cancer is currently advancing to the locally advanced setting, although preliminary efficacy outcomes in this setting have been disappointing so far. Moreover, promising data are emerging from early-phase trials on novel immunotherapy approaches, such as human papillomavirus therapeutic vaccines and adoptive cell therapy. This review summarizes the main clinical trials carried out in the field of immunotherapy in the last several years.
MEMBER ACCOUNT
登录成功会直接打开下一页。
